ImmunoBiology Limited-Product Pipeline Review-2015

ImmunoBiology Limited-Product Pipeline Review-2015

  • Products Id :- GMDHC07208CDB
  • |
  • Pages: 24
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

ImmunoBiology Limited-Product Pipeline Review-2015


Global Markets Direct's, 'ImmunoBiology Limited-Product Pipeline Review-2015', provides an overview of the ImmunoBiology Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ImmunoBiology Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of ImmunoBiology Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of ImmunoBiology Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the ImmunoBiology Limited's pipeline products

Reasons To Buy

Evaluate ImmunoBiology Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of ImmunoBiology Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the ImmunoBiology Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of ImmunoBiology Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of ImmunoBiology Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of ImmunoBiology Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

ImmunoBiology Limited Snapshot 5

ImmunoBiology Limited Overview 5

Key Information 5

Key Facts 5

ImmunoBiology Limited-Research and Development Overview 6

Key Therapeutic Areas 6

ImmunoBiology Limited-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

ImmunoBiology Limited-Pipeline Products Glance 10

ImmunoBiology Limited-Early Stage Pipeline Products 10

Preclinical Products/Combination Treatment Modalities 10

Discovery Products/Combination Treatment Modalities 11

ImmunoBiology Limited-Drug Profiles 12

FluBioVax 12

Product Description 12

Mechanism of Action 12

R&D Progress 12

MenBioVax 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

PnuBioVax 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

T-BioVax 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

Clostridium difficile vaccine 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

helicobacter pylori vaccine 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Hepatitis C Vaccine 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

ImmunoBiology Limited-Pipeline Analysis 19

ImmunoBiology Limited-Pipeline Products by Target 19

ImmunoBiology Limited-Pipeline Products by Molecule Type 20

ImmunoBiology Limited-Recent Pipeline Updates 21

ImmunoBiology Limited-Locations And Subsidiaries 22

Head Office 22

Appendix 23

Methodology 23

Coverage 23

Secondary Research 23

Primary Research 23

Expert Panel Validation 23

Contact Us 23

Disclaimer 24

List of Tables

ImmunoBiology Limited, Key Information 5

ImmunoBiology Limited, Key Facts 5

ImmunoBiology Limited-Pipeline by Indication, 2015 7

ImmunoBiology Limited-Pipeline by Stage of Development, 2015 8

ImmunoBiology Limited-Monotherapy Products in Pipeline, 2015 9

ImmunoBiology Limited-Preclinical, 2015 10

ImmunoBiology Limited-Discovery, 2015 11

ImmunoBiology Limited-Pipeline by Target, 2015 19

ImmunoBiology Limited-Pipeline by Molecule Type, 2015 20

ImmunoBiology Limited-Recent Pipeline Updates, 2015 21

List of Figures

ImmunoBiology Limited-Pipeline by Top 10 Indication, 2015 7

ImmunoBiology Limited-Pipeline by Stage of Development, 2015 8

ImmunoBiology Limited-Monotherapy Products in Pipeline, 2015 9

ImmunoBiology Limited-Pipeline by Top 10 Target, 2015 19

ImmunoBiology Limited-Pipeline by Top 10 Molecule Type, 2015 20

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of ImmunoBiology Limited; ImmunoBiology Limited - Key Therapeutics; ImmunoBiology Limited - Pipeline Overview and Promising Molecules; ImmunoBiology Limited - News; ImmunoBiology Limited - Latest Updates; ImmunoBiology Limited - Pipeline; ImmunoBiology Limited - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102105
Site License
USD 3000 INR 204210
Corporate User License
USD 4500 INR 306315



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]